<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The feasibility and efficacy of up-front high-dose sequential chemotherapy followed by autologous stem cell transplantation (ASCT) in previously untreated adults (median age 33 years; range 15-64) with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>) or lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LyLy), both without central <z:mp ids='MP_0008912'>nervous</z:mp> system or extensive bone marrow involvement was investigated in a multicenter phase II study </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment consisted of two sequential high-dose chemotherapy induction courses incorporating <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi> and <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi>, without high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> or high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with at least PR went on with BEAM and ASCT </plain></SENT>
<SENT sid="3" pm="."><plain>Protocol treatment was completed by 23/27 (85%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> and 13/15 (87%) LyLy patients </plain></SENT>
<SENT sid="4" pm="."><plain>Median treatment duration until BEAM was 70 (range: 50-116) days </plain></SENT>
<SENT sid="5" pm="."><plain>No toxic <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred </plain></SENT>
<SENT sid="6" pm="."><plain>Response to treatment was complete response (CR) 81% and partial response (PR) 11% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>, CR 73% and PR 20% for LyLy </plain></SENT>
<SENT sid="7" pm="."><plain>At a median follow-up of 61 months of patients still alive, six <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> and eight LyLy patients have died </plain></SENT>
<SENT sid="8" pm="."><plain>The actuarial 5-year overall and event-free survival estimates are 81 and 73% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> vs 46 and 40% for LyLy patients </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, this short up-front high-dose sequential chemotherapy regimen, followed by ASCT is highly effective in adults with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> with limited bone marrow involvement, but less so in patients with LyLy </plain></SENT>
</text></document>